mRNA vaccines
The Molecule That Spent Thirty Years Being Wrong Before It Saved the World
The technology behind the COVID-19 vaccines was considered a dead end for so long that the scientist who believed in it most was stripped of her university position and told to find something more promising to work on.
The Idea
Every cell in your body runs on a kind of molecular whisper network. DNA holds the master instructions, but it rarely leaves the nucleus — instead, it dispatches single-stranded messenger molecules called mRNA to carry temporary recipes to the cell's protein-making machinery. The idea behind mRNA vaccines is elegant: skip the virus entirely, and just deliver the recipe. Give your cells the instructions to build one small, harmless piece of a pathogen — a spike protein, say — and your immune system will learn to recognise it without ever encountering the real threat. The concept had been floated since the late 1980s, but it ran into a stubborn problem: synthetic mRNA injected into the body triggered violent immune responses, attacking the messenger before it could deliver its message. For two decades, the field limped along as a fringe interest. The breakthrough came when biochemist Katalin Karikó and immunologist Drew Weissman discovered that swapping one of the molecular building blocks of synthetic mRNA — a nucleoside called uridine — for a slightly modified version called pseudouridine rendered it nearly invisible to the immune system. The body stopped treating it as an invader and started reading it as instructions. That single chemical substitution, published in 2005 and largely ignored at the time, is the reason mRNA vaccines work at all.
In the World
Katalin Karikó spent much of the 1990s at the University of Pennsylvania fighting for grant money nobody wanted to give her. She was demoted in 1995 — told, in effect, that mRNA research was not a serious career. She stayed anyway, running experiments on a shoestring, and in 1997 she met Drew Weissman in a photocopying queue. He was an immunologist looking for a better way to develop an HIV vaccine; she told him mRNA might be the answer. They began collaborating. Their 2005 paper on modified nucleosides was a landmark that almost nobody noticed. It took another decade and two young biotech companies — Moderna, founded in 2010, and BioNTech, co-founded by Uğur Şahin and Özlem Türeci in 2008 — to turn that chemistry into a platform capable of rapid deployment. When SARS-CoV-2 emerged in early 2020, both companies had the genetic sequence of the virus's spike protein within days and began designing their vaccines almost immediately. Moderna dosed its first clinical trial participant on the 16th of March 2020 — just 66 days after the sequence was published. The speed wasn't luck or shortcuts. It was the result of a platform that had been quietly refined for fifteen years, waiting for a moment exactly like this. Karikó and Weissman received the Nobel Prize in Physiology or Medicine in 2023.
Why It Matters
What strikes most people about mRNA technology, once they understand it, is how it inverts the traditional logic of vaccine development. Conventional vaccines require you to grow, weaken, or fragment an actual pathogen — a slow, expensive, facility-intensive process. mRNA vaccines require only a genetic sequence. As long as you can read the virus's code, you can begin designing a response. That is a genuinely different relationship with infectious disease. The implications stretch well beyond COVID-19. Clinical trials are already underway for personalised mRNA cancer vaccines — treatments tailored to the specific mutations in an individual tumour, designed to train the immune system to hunt down those particular cells. Influenza, HIV, and even some autoimmune conditions are in early-stage research. There is also a quieter lesson here about the shape of scientific progress. The Karikó story is a useful corrective to the idea that good science gets recognised quickly. It often doesn't. Some of the most important work happens at the edge of institutional attention, sustained by people who believe in something long before the world catches up.
A Question to Ponder
If a medical technology is genuinely promising but decades away from practical use, how should research institutions decide what to fund — and who bears the cost when they get it wrong?
Get a new one of these every morning.
Start learning with Thinkable